BMEA · Biomea Fusion, Inc.
$1.22
-0.03 (-2.40%)
At close · Jul 29
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that the existing financial resources are not sufficient to continue operating activities for at least twelve months past the issuance date of these unaudited condensed financial statements. The Company's ability to continue as a going concern will require the Company to raise additional capital to fund the Company's operations through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. There can be no assurance that additional financing will be available to the Company or that such financing, if available, will be available on terms acceptable to the Company. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 11, 2026
Market Cap
$88.21M
Shares
72.30M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$61.8M
+55.4%
FY2025
Diluted EPS
-$1.18
+69.2%
FY2025
Operating Cash Flow
-$70.37M
+41.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $1.84M | $1.86M | $5.64M | $8.88M | — | — | — | — | |
| $48.2M | $61.98M | $118.09M | $102.55M | $62.71M | $28M | $3.67M | $1.09M | |
| $16.17M | $19.33M | $25.99M | $23.59M | $20.92M | $13.67M | $1.66M | $103K | |
| $66.57M | $83.51M | $144.07M | $126.14M | $83.63M | $41.67M | $5.33M | $1.2M | |
| -$66.57M | -$83.51M | -$144.07M | -$126.14M | -$83.63M | -$41.67M | -$5.33M | -$1.2M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$44.95M | -$61.8M | -$138.43M | -$117.26M | -$81.83M | -$41.57M | -$5.32M | -$1.2M | |
| -$44.95M | -$61.8M | -$138.43M | -$117.25M | -$81.82M | -$41.58M | -$5.32M | -$1.2M | |
| USD/shares | — | -$1.18 | -$3.83 | -$3.44 | -$2.80 | -$1.74 | -$0.51 | — |
| USD/shares | — | -$1.18 | -$3.83 | -$3.44 | -$2.80 | -$1.74 | -$0.51 | — |
| shares | — | 52.23M | 36.11M | 34.11M | 29.27M | 23.86M | 10.53M | 6.05M |
| shares | — | 52.23M | 36.11M | 34.11M | 29.27M | 23.86M | 10.53M | 6.05M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.10×
EV/EBIT
—
Peer median 26.45×
P/E (TTM)
—
Peer median 3.87×
Peer medians compare against the 297 similar-size Biotechnology companies (of 522 listed).
Key facts
CIK
1840439
CUSIP
09077A106
13F (30d)
10 filings
10 filers
Visit website
Investor relations